Wing L M, Miners J O, Lillywhite K J
Br J Clin Pharmacol. 1985 Mar;19(3):385-91. doi: 10.1111/j.1365-2125.1985.tb02658.x.
The effects of separate 7 day pretreatments with sulphinpyrazone (800 mg daily) and cimetidine (1 g daily) on the disposition of (+/-)-verapamil have been examined in eight healthy volunteers (four male, four female). Each subject received single oral (80 mg) and intravenous (0.15 mg/kg) doses of verapamil on different occasions before and after each pretreatment. Following sulphinpyrazone pretreatment, verapamil apparent oral plasma clearance (CLpo) increased from 4.27 to 13.77 l h-1 kg-1 (s.e. mean 0.51--ANOVA) (P less than 0.001); CL increased from 1.05 to 1.20 l h-1 kg-1 (s.e. mean 0.05) (P less than 0.05) and Fpo decreased from 27 to 10% administered dose (s.e. mean 2) (P less than 0.001). Vss and t1/2,z were unchanged. There was no sex difference for any dispositional parameter in the control phase, but the increase in CLpo following sulphinpyrazone pretreatment was more marked in males (4.04 to 17.33 l h-1 kg-1) than in females (4.49 to 10.21 l h-1 kg-1) (s.e. mean 0.72) (P less than 0.01). There was no significant change in any verapamil disposition parameter following cimetidine pretreatment. Verapamil unbound fraction in plasma was 0.157 (s.e. mean 0.001, n = 40). There was no alteration in verapamil plasma protein binding associated with increasing verapamil concentration (25-250 micrograms l-1) or addition of sulphinpyrazone (50-500 mg l-1) or cimetidine (0.5-5 mg l-1). The results suggest that sulphinpyrazone induces the metabolic clearance of (+/-)-verapamil with a sex difference in the response.(ABSTRACT TRUNCATED AT 250 WORDS)
在8名健康志愿者(4名男性,4名女性)中研究了分别用磺吡酮(每日800毫克)和西咪替丁(每日1克)进行7天预处理对(±)-维拉帕米处置的影响。在每次预处理前后的不同时间,每位受试者均接受了单次口服(80毫克)和静脉注射(0.15毫克/千克)剂量的维拉帕米。磺吡酮预处理后,维拉帕米的表观口服血浆清除率(CLpo)从4.27升/小时·千克增加至13.77升/小时·千克(标准误均值0.51——方差分析)(P<0.001);CL从1.05升/小时·千克增加至1.20升/小时·千克(标准误均值0.05)(P<0.05),Fpo从给药剂量的27%降至10%(标准误均值2)(P<0.001)。稳态分布容积(Vss)和终末消除半衰期(t1/2,z)未改变。在对照期,任何处置参数均无性别差异,但磺吡酮预处理后CLpo的增加在男性中(4.04至17.33升/小时·千克)比女性中(4.49至10.21升/小时·千克)更显著(标准误均值0.72)(P<0.01)。西咪替丁预处理后,任何维拉帕米处置参数均无显著变化。血浆中维拉帕米的未结合分数为0.157(标准误均值0.001,n = 40)。随着维拉帕米浓度增加(25 - 250微克/升)或加入磺吡酮(50 - 500毫克/升)或西咪替丁(0.5 - 5毫克/升),维拉帕米的血浆蛋白结合无改变。结果表明,磺吡酮诱导(±)-维拉帕米的代谢清除,且反应存在性别差异。(摘要截短至250字)